Introduction: The Common Technical Document (CTD) is a harmonized format for submitting information to regulatory authorities when seeking approval for pharmaceuticals. This blog provides M.Pharm students with focused, exam-oriented MCQs covering CTD structure, module contents, eCTD technical aspects, and regulatory expectations. Questions probe Module 1 region-specific items, Modules 2–5 summaries and detailed sections, and practical considerations such as sequence management, backbone/leaf file concepts, and validation checks. Designed for clarity and depth, these MCQs will help students master documentation and regulatory writing concepts essential for dossier preparation, review, and lifecycle management of drug submissions in global regulatory environments.
Q1. What is the primary purpose of the Common Technical Document (CTD)?
- To harmonize the format and content of information submitted to regulatory authorities for drug approval
- To replace all national regulations with a single global law
- To provide marketing material for pharmaceutical products
- To function as an internal manufacturing SOP
Correct Answer: To harmonize the format and content of information submitted to regulatory authorities for drug approval
Q2. How many modules are defined in the CTD structure?
- Three modules
- Four modules
- Five modules
- Six modules
Correct Answer: Five modules
Q3. Which module of the CTD contains region-specific administrative and prescribing information?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 1
Q4. Which of the following documents is included in Module 2 of the CTD?
- Quality Overall Summary (QOS)
- Clinical Study Reports
- Manufacturing Batch Records
- Labeling and package insert
Correct Answer: Quality Overall Summary (QOS)
Q5. Module 3 of the CTD primarily addresses which of the following?
- Nonclinical pharmacology and toxicology
- Clinical efficacy and safety
- Chemistry, Manufacturing and Controls (CMC) information
- Administrative and regional information
Correct Answer: Chemistry, Manufacturing and Controls (CMC) information
Q6. What is the main difference between Module 4 and Module 5 in the CTD?
- Module 4 covers clinical trials; Module 5 covers formulation details
- Module 4 contains nonclinical study reports; Module 5 contains clinical study reports
- Module 4 is region-specific; Module 5 is harmonized globally
- Module 4 includes labeling; Module 5 includes pharmacopoeial monographs
Correct Answer: Module 4 contains nonclinical study reports; Module 5 contains clinical study reports
Q7. Which ICH guideline formally established the CTD format?
- ICH M1
- ICH M2
- ICH M4
- ICH E3
Correct Answer: ICH M4
Q8. In the eCTD, what does a “sequence” refer to?
- A single PDF file containing the entire dossier
- An ordered set of documents representing a submission or an update to the dossier
- A manufacturing batch number
- The numbering scheme for Module 3 subsections
Correct Answer: An ordered set of documents representing a submission or an update to the dossier
Q9. Which of the following best describes the “backbone” in an eCTD submission?
- The physical binder used to mail the application
- The hierarchical folder structure that defines navigation and metadata
- The cover letter of the submission
- The stability data tables in Module 3
Correct Answer: The hierarchical folder structure that defines navigation and metadata
Q10. In CTD section numbering, what does 3.2.P typically represent?
- Clinical study protocols
- Drug product (pharmaceutical) information
- Drug substance (active ingredient) information
- Nonclinical toxicology reports
Correct Answer: Drug product (pharmaceutical) information
Q11. Which document is usually found in Module 2.4 of the CTD?
- Nonclinical Overview
- Clinical Summary
- Nonclinical Written and Tabulated Summaries
- Quality Overall Summary (QOS)
Correct Answer: Nonclinical Written and Tabulated Summaries
Q12. Which of the following is a key objective of the Quality Overall Summary (QOS) in Module 2?
- To provide full raw analytical data for each batch
- To summarize the critical quality attributes and justifications for the drug substance and product
- To list all regional regulatory contacts
- To provide patient-level clinical data
Correct Answer: To summarize the critical quality attributes and justifications for the drug substance and product
Q13. Which Module 1 item is typically region-specific and not part of the harmonized CTD core?
- Module 3.2.P.2 Pharmaceutical Development
- Investigational New Drug (IND) application forms (USA)
- Module 2.5 Clinical Summary
- Nonclinical study reports from Module 4
Correct Answer: Investigational New Drug (IND) application forms (USA)
Q14. Which of the following is a required element for eCTD validation in many regulatory agencies?
- Proof of product sales in at least three countries
- Correct MIME types and valid XML backbone files
- Physical hard copies of all Module 3 documents
- Hand-signed original clinical study reports
Correct Answer: Correct MIME types and valid XML backbone files
Q15. In CTD Module 3, where would you find stability study reports for the drug product?
- 3.2.S.3
- 3.2.P.8
- 3.2.A
- 2.7
Correct Answer: 3.2.P.8
Q16. Which statement best explains the relationship between Module 2 and Modules 3–5?
- Module 2 contains full study reports; Modules 3–5 contain only summaries
- Module 2 provides expert overviews and summaries of the detailed data found in Modules 3–5
- Module 2 is optional if Modules 3–5 are complete
- Modules 3–5 are only required for biologics, not small molecules
Correct Answer: Module 2 provides expert overviews and summaries of the detailed data found in Modules 3–5
Q17. What does “granularity” refer to in the context of an eCTD submission?
- The particle size of the drug substance
- The level of file division and organization into logical PDF documents and nodes
- The number of pages in the clinical overview
- The solvent residues specification
Correct Answer: The level of file division and organization into logical PDF documents and nodes
Q18. Which of the following is a common reason for regulatory authorities to issue a “refuse to file” based on CTD/eCTD submissions?
- Minor typographical errors throughout the dossier
- Missing critical Module 1 administrative documents or unacceptable eCTD validation failures
- Having data from multiple clinical sites
- Including both Module 3 and Module 5 data
Correct Answer: Missing critical Module 1 administrative documents or unacceptable eCTD validation failures
Q19. Which section of the CTD would include pharmacokinetic study reports from human clinical trials?
- Module 3
- Module 4
- Module 5
- Module 2.1
Correct Answer: Module 5
Q20. For global submissions, which strategy helps minimize region-specific duplication while respecting CTD structure?
- Placing all regional documents in Module 2
- Using Module 1 for region-specific items and keeping Modules 2–5 harmonized across regions
- Submitting separate complete dossiers for each region without CTD structure
- Including regional labels within Module 3 to avoid Module 1
Correct Answer: Using Module 1 for region-specific items and keeping Modules 2–5 harmonized across regions
